Moreover, when tumor-bearing mice received an OVA peptide/CpG-ODN vaccination combined with systemic treatments of αGalCer/CD1d-antitumor fusion proteins, a synergistic expansion of OVA-specific CD8 T cells and NK cells was obtained, as compared to each regimen alone (12). Here, CD1D is linked to neoplasm.